Corcept Therapeutics
CORT
226 hedge funds and large institutions have $2.18B invested in Corcept Therapeutics in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 60 increasing their positions, 94 reducing their positions, and 32 closing their positions.
41% more capital invested
Capital invested by funds: $1.55B → $2.18B (+$630M)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
1% more funds holding
Funds holding: 223 → 226 (+3)
9% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 32
4% more call options, than puts
Call options by funds: $23.9M | Put options by funds: $22.9M
5.33% less ownership
Funds ownership: 77.11% → 71.78% (-5.3%)
36% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$11.9M |
| 2 |
BlackRock
New York
|
+$9.93M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$8.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.57M |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
+$5.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$25M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$18.2M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$12.3M |
| 4 |
Man Group
London,
United Kingdom
|
-$9.48M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$7.47M |
CORT Hedge Fund Activity: Q4 2020 in Review
226 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2020, worth a combined $2.18B — up 41% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CORT positions and 32 closed out — a net gain of 3 holders — while 60 added to existing stakes and 94 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $11.9M. The largest seller was Invesco, cutting an estimated $25M.
- 226 institutional investors held Corcept Therapeutics (CORT) as of Q4 2020, up from 223 in Q3 2020.
- Funds reported $2.18B of Corcept Therapeutics stock for Q4 2020, up 41% quarter-over-quarter.
- 35 funds opened new Corcept Therapeutics positions in Q4 2020 and 32 closed out, a net change of +3 holders.
- The largest Corcept Therapeutics buyer in Q4 2020 was Woodline Partners, an estimated $11.9M added.
- The largest Corcept Therapeutics seller in Q4 2020 was Invesco, an estimated $25M sold.
Based on aggregated 13F filings for Q4 2020.